about
A biomechanical, micro-computertomographic and histological analysis of the influence of diclofenac and prednisolone on fracture healing in vivo.Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cellsOsteoclast inhibitory lectin, a family of new osteoclast inhibitorsIncreasing membrane-bound MCSF does not enhance OPGL-driven osteoclastogenesis from marrow cells.Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation.Kruppel-like factor 4 attenuates osteoblast formation, function, and cross talk with osteoclastsThe molecular genetics of bone formation: implications for therapeutic interventions in bone disorders.Runx2, a multifunctional transcription factor in skeletal development.Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fracturesBone remodeling in post-menopausal osteoporosis.Runx2 and dental development.Molecular actions of 1,25-dihydroxyvitamin D3 on genes involved in calcium homeostasis.DACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells.SMURF2 regulates bone homeostasis by disrupting SMAD3 interaction with vitamin D receptor in osteoblastsSp1 and Sp3 regulate the basal transcription of receptor activator of nuclear factor kappa B ligand gene in osteoblasts and bone marrow stromal cells.Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligandEpigenetics and Bone Remodeling.Rab27a and Rab27b are involved in stimulation-dependent RANKL release from secretory lysosomes in osteoblastic cells.Modulation of mouse RANKL gene expression by Runx2 and PKA pathway.The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells.Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion.Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells.RANK ligand is a prerequisite for cancer-associated osteolytic lesions.1Alpha,25-dihydroxyvitamin D3 promotes vascularization of the chondro-osseous junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 9.Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone.RANKL expression is related to the differentiation state of human osteoblasts.Modulation of mouse RANKL gene expression by Runx2 and vitamin D3.In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer.Identification of RANKL in osteolytic lesions of the facial skeleton.[6]-Gingerol induces bone loss in ovary intact adult mice and augments osteoclast function via the transient receptor potential vanilloid 1 channel.Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts.Expression profile of genes related to osteoclastogenesis in mouse growth plate and articular cartilage.Analysis of the association of polymorphism in the osteoprotegerin gene with susceptibility to chronic kidney disease and periodontitis.
P2860
Q27309225-909EF1F0-BB59-4FF6-83DA-E8B782E30E5DQ28236662-D076D5D6-4D5A-4AE6-AD1E-3C1ED7C69440Q28507297-BDCD2FE5-103E-4524-9E4F-6752F8793E85Q31712554-CF68B0AF-9DA2-4629-BB20-C74161EEC672Q31717820-406A350E-B3B5-4AC7-9612-D85F9A5852D5Q34409480-C265B97C-A2C8-452A-AAAF-17A32A5F0BE3Q34574012-26036D3A-4077-43A5-A824-91FC464584AEQ34811834-EEE50861-AB7E-42CF-B36A-C85CFB643C2AQ36293998-A3F14F12-0A51-4CAC-84AD-820C18039CE0Q36518536-F0A08708-04F4-44F7-AEFE-6C588A31E423Q36616577-78D94360-1D0E-4C1B-92CB-1E6B48245187Q37090974-A7B00F9C-3200-440B-90A8-79E380606053Q37424820-194FF08A-C811-4A47-A81D-407531CCC344Q37660607-78FCBEF1-2CA1-45D8-9053-9076C31406E2Q38323003-6D45290C-0D19-4463-88B2-1E4768A3E93CQ38515705-08D37886-578F-4ACC-A6B8-94C6394D51D7Q38624611-7F13B7C6-C9FB-47A6-B001-2A264FF3D640Q39645396-49EE0914-A257-4EE5-A9ED-D9EB912DCEDEQ40295089-9E02FF2A-AA08-4A12-AD69-4E2715D61DD3Q40333911-DA2424FA-381A-41AF-9C1E-F92FE381CF24Q40350049-0F90F6AA-E0F4-45F7-9E02-4BDC5886CD4AQ40511365-E86BDB23-C266-4E6E-8F38-2CC91C33D3F4Q40703245-0059AE16-FBA8-4EFF-A7E2-784966E156E8Q40706565-49554230-CBD0-4E2F-B8EC-E42580CA7389Q43993807-8FCB8092-B26C-483A-BE64-1817F8C07E65Q44484957-C8E718CA-44E3-4887-91AB-02B902BD2CA2Q46349706-DA962742-665B-4E6F-B943-70EF36E4C579Q47816427-71BEC8BD-0B56-4F5D-84B8-06C3BBC3BD8FQ47880647-60CED13A-BF29-403F-B9DD-D007DB975887Q51306052-43C00BA5-F614-4AC1-A752-B29E7178A264Q52551676-D5D14213-6318-4935-8129-08840FA2D8D7Q53649562-B49B79A3-117B-429D-9652-79569854FEF1Q54524679-D4CE21FC-1E3C-4A43-A4F3-B73FA521107E
P2860
description
article
@en
im April 1999 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 1999
@uk
name
Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene
@en
Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene
@nl
type
label
Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene
@en
Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene
@nl
prefLabel
Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene
@en
Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene
@nl
P2093
P1476
Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene
@en
P2093
P304
P356
10.1016/S0167-4781(99)00032-9
P577
1999-04-01T00:00:00Z